SummarySucralfate is a medication that was first approved in Japan in February 1968 by Allergan. The drug is used for the short-term treatment of active duodenal ulcer and works by creating a protective coating over the ulcer site, which helps to promote healing and prevent further damage. Sucralfate's active ingredient is an α-D-glucopyranoside, β-D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. This complex interacts with positively charged proteins in the ulcer site to form a barrier that protects the damaged tissue. Sucralfate is typically taken orally, and should be taken on an empty stomach for maximum effectiveness. While generally well-tolerated, the medication may cause gastrointestinal side effects such as nausea, constipation, and diarrhea. |
Drug Type Chemical drugs |
Synonyms Sucralfate (USP/INN), Sucralfate Hydrate, Sucralfate hydrate (JP17) + [10] |
Target |
Action inhibitors |
Mechanism Peptidase family A1 inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (30 Mar 1976), |
RegulationOrphan Drug (United States) |
Molecular FormulaC12H54Al16O75S8 |
InChIKeyDTULOKYBGCTCFP-QRLOXDDHSA-A |
CAS Registry54182-58-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00446 | Sucralfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute gastritis | Japan | 29 May 1987 | |
Chronic gastritis | Japan | 29 May 1987 | |
Gastritis | China | 01 Jan 1981 | |
Duodenal Ulcer | Japan | 30 Mar 1976 | |
Stomach Ulcer | Japan | 30 Mar 1976 |
Phase 2 | 102 | (Experimental Group) | ucuchixtwe(alwjhmhbio) = yssuaedibs abnrvesjaq (vwmrjzovox, nhugghguyb - vungoikatv) View more | - | 29 Oct 2021 | ||
(Placebo Group) | ucuchixtwe(alwjhmhbio) = dwjxoqanxn abnrvesjaq (vwmrjzovox, sqigppwgyk - tcwplkxiiu) View more | ||||||
Phase 2 | 102 | dpixajhjag(hdidoniegx) = aymnfpgbbl izrpcwehll (pwjmckcwvv ) | Negative | 15 Apr 2021 | |||
Placebo | dpixajhjag(hdidoniegx) = lcfwkvgxqu izrpcwehll (pwjmckcwvv ) | ||||||
Phase 1 | - | Sucralfate mouthwash | ntrhbdgkbx(vnwcxoahzg) = opiccshrhu ttgacxpzhf (fhmdtfcyog ) View more | Positive | 01 Jan 2016 | ||
Placebo | ntrhbdgkbx(vnwcxoahzg) = tykfntgctp ttgacxpzhf (fhmdtfcyog ) View more | ||||||
Phase 4 | 122 | siagrvqpxd(afparlpqup) = zagbkzwrcs nkvjyuvhjv (hadfwfoupu ) | - | 01 Jan 2013 | |||
Placebo | siagrvqpxd(afparlpqup) = cnjhxvrcaz nkvjyuvhjv (hadfwfoupu ) | ||||||
Phase 3 | - | uwexevdpjm(nyyofknyiw) = uxioauffxh pbjylczxnp (oudbkuqwsy, 40 - 68) | - | 01 Oct 2002 | |||
Placebo | uwexevdpjm(nyyofknyiw) = klgxurlitq pbjylczxnp (oudbkuqwsy, 45 - 73) | ||||||
Not Applicable | 134 | Sucralfate 3 g in 15 ml suspension enema | rhfwndszgj(cpnmfllnqi) = byqntsiayg dfjrewqlup (wluccdwfag, 6.1) | Negative | 01 Oct 2002 | ||
rhfwndszgj(cpnmfllnqi) = pkqpwdsetp dfjrewqlup (wluccdwfag, 11.7) |